BCM-95 and (2-hydroxypropyl)-β-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in Sap C-deficient fibroblasts

Human Molecular Genetics

Volumn 24, Issue 15, 2015, Pages 4198-4211

  Tatti, Massimo ^a   Motta, Marialetizia ^a   Scarpa, Susanna ^b   Di Bartolomeo, Sabrina ^c   Cianfanelli, Valentina ^c,d   Tartaglia, Marco ^a   Salvioli, Rosa ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BCM 95; CATHEPSIN B; CATHEPSIN D; CERAMIDE; CURCUMIN; SPHINGOLIPID ACTIVATOR PROTEIN; BETA CYCLODEXTRIN DERIVATIVE; CTSD PROTEIN, HUMAN; GLUCOSYLCERAMIDE;

APOPTOSIS; ARTICLE; AUTOLYSOSOME; AUTOPHAGY (CELLULAR); CELL DYSFUNCTION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; FIBROBLAST; FLOW CYTOMETRY; GAUCHER DISEASE; GENETIC DISORDER; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE ASSAY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; LIPIDOSIS; MTS ASSAY; PHASE CONTRAST MICROSCOPY; PROPIDIUM IODIDE ASSAY; SAPOSIN C DEFICIENCY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; AUTOPHAGY; BIOSYNTHESIS; DEFICIENCY; DRUG EFFECTS; GENETICS; LYSOSOME; METABOLISM; PATHOLOGY;

AUTOPHAGY; BETA-CYCLODEXTRINS; CATHEPSIN B; CATHEPSIN D; CURCUMIN; FIBROBLASTS; GAUCHER DISEASE; GLUCOSYLCERAMIDES; HUMANS; LYSOSOMES; SAPOSINS;

EID: 84973425995     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv153     Document Type: Article

References (43)

1. Sandhoff, K., Kolter, T. and Harzer, K. (2001) Sphingolipid activator proteins. In Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W. and Vogelstein, B. (eds), The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill, New York, pp. 3371–3388.
2. Beutler, E. and Grabowski, G.A. (2001) Gaucher disease. In Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W. and Vogelstein, B. (eds), The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill, New York, pp. 3635–3668.
3. Christomanou, H., Aignesberger, A. and Link, R.P. (1986) Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol. Chem. Hoppe Seyler, 367, 879–890.
4. Christomanou, H., Chabas, A., Pampols, T. and Guardiola, A. (1989) Activator protein deficient Gaucher’s disease. A second patient with the newly identified lipid storage disorder. Klin. Wochenschr., 67, 999–1003.
5. Rafi, M.A., de Gala, G., Zhang, X.L. and Wenger, D.A. (1993) Mutational analysis in a patient with a variant form of Gaucher disease caused by Sap-2 deficiency. Somat. Cell. Mol. Genet., 19, 1–7.
6. Tylki-Szymanska, A., Czartoryska, B., Vanier, M.T., Poorthuis, B.J., Groener, J.A., Lugowska, A., Millat, G., Vaccaro, A.M. and Jurkiewicz, E. (2007) Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin. Genet., 72, 538–542.
7. Vanier, M.T. and Millat, G. (2009) Are sphingolipid activator deficiencies underdiagnosed? Int. J. Clin. Pharmacol. Therap., 47(Suppl. 1), S147–S148.
8. Amsallem, D., Rodriguez, D., Vanier, M.T., Khayat, N., Millat, G., Campello, M., Guillame, C. and Billette De Villemeur, T. (2005) Third case of Gaucher disease with sap-C deficiency and evaluation of twelve months’ therapy by miglustat. J. Inherit. Metab. Dis., 28(Suppl. 1), 152.
9. Klionsky, D.J. and Emr, S.D. (2000) Autophagy as a regulated pathway of cellular degradation. Science, 290, 1717–1721.
10. Shintani, T. and Klionsky, D.J. (2004) Autophagy in health and disease: a double-edged sword. Science, 306, 990–995.
11. Motta, M., Camerini, S., Tatti, M., Casella, M., Torreri, P., Crescenzi, M., Tartaglia, M. and Salvioli, R. (2014) Gaucher disease due to saposin C deficiency is an inherited lysosomal disease caused by rapidly degraded mutant proteins. Hum. Mol. Genet., 23, 5814–5826.
12. Vaccaro, A.M., Motta, M., Tatti, M., Scarpa, S., Masuelli, L., Bhat, M., Vanier, M.T., Tylki-Szymanska, A. and Salvioli, R. (2010) Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum. Mol. Genet., 19, 2987–2997.
13. Tatti, M., Motta, M., Di Bartolomeo, S., Scarpa, S., Cianfanelli, V., Cecconi, F. and Salvioli, R. (2012) Reduced cathepsins B and D cause impaired autophagic degradation that can be almost completely restored by overexpression of these two proteases in Sap C-deficient fibroblasts. Hum. Mol. Genet., 21, 5159–5173.
14. Lachmann, R.H. and Platt, F.M. (2001) Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin. Investig. Drugs, 10, 455–466.
15. Tylki-Szymanska, A., Groener, J.E., Kaminski, M.L., Lugowska, A., Jurkiewicz, E. and Czartoryska, B. (2011) Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form- no positive effects after 2-years of miglustat therapy. Mol. Genet. Metab., 104, 627–630.
16. Antony, B., Merina, B., Iyer, V.S., Judy, N., Lennertz, K. and Joyal, S. (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel biohenanced preparation of curcumin. Indian J. Pharm. Sci., 70, 445–449.
17. Aggarwal, B.B., Sethi, G., Baladandaythapani, V., Krishnan, S. and Shishodia, S. (2007) Targeting cell signalling pathways for drug discovery: an old lock needs a new key. J. Cell Biochem., 102, 580–592.
18. Motterlini, R., Foresti, R., Bassi, R. and Green, C.J. (2000) Curcumin, an anti-oxidant and anti-inflammatory agent, induces heme oxigenase-1 and protects endothelial cells against oxidative stress. Free Radic. Biol. Med., 28, 1303–1312.
19. Hasima, N. and Aggarwal, B.B. (2012) Cancer-linked targets modulated by curcumin. Int. J. Biochem. Mol. Biol., 3, 328–351.
20. Neufeld, E.B., Cooney, A.M., Pitha, J., Dawidowicz, E.A., Dwyer, N.K., Pentchev, P.G. and Blanchette-Mackie, E.J. (1996) Intracellular trafficking of cholesterol monitored with a cyclodextrin. J. Biol. Chem., 271, 21604–21613.
21. Liu, B., Turley, S.D., Burns, D.K., Miller, A.M., Repa, J.J. and Dietschy, J.M. (2009) Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc. Natl. Acad. Sci. USA, 106, 2377–2382.
22. Rosenbaum, A.I., Zhang, G., Warren, J.D. and Maxfield, F.R. (2010) Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc. Natl. Acad. Sci. USA, 107, 5477–5482.
23. Aqul, A., Liu, B., Ramirez, C.M., Pieper, A.A., Estill, S.J., Burns, D.K., Liu, B., Repa, J.J., Turley, S.D. and Dietschy, J.M. (2011) Unesterified cholesterol accumulation in late endosomes/ lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J. Neurosci., 31, 9404–9413.
24. Taylor, A.M., Liu, B., Mari, Y., Liu, B. and Repa, J.J. (2012) Cyclodextrin mediates rapid changes in lipid balance in Npc1-/mice without carrying cholesterol through the bloodstream. J Lipid Res., 53, 2331–2342.
25. Zhang, D., Huang, C., Yang, C., Liu, R.J., Wang, J. and Brömme, D. (2011) Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Respir. Res., 12, 154–165.
26. Tanida, I., Minematsu-Ikeguchi, N., Ueno, T. and Kominami, E. (2005) Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy, 1, 84–91.
27. Pankiv, S., Clausen, T.H., Lamark, T., Brech, A., Bruun, J.A., Outzen, H., Overvatn, A., Biorkoy, G. and Johansen, T. (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem., 282, 24131–24145.
28. Vazquez, C.L. and Colombo, M.I. (2009) Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ-BSA. Methods Enzymol., 452, 85–95.
29. Korolchuk, V.I., Saiki, S., Lichtenberg, M., Siddiqi, F.H., Roberts, E.A., Imarisio, S., Jahreiss, L., Sarkar, S., Futter, M., Menzies, F.M. et al. (2011) Lysosomal positioning coordinates cellular nutrient responses. Nat. Cell Biol., 13, 453–460.
30. Davidson, C.D., Ali, N.F., Micsenyi, M.C., Stephney, G., Renault, S., Dobrenis, K., Ory, D.S., Vanier, M.T. and Walkley, S.U. (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLOS ONE, 4, e6951.
31. Peschel, D., Koerting, R. and Nass, N. (2007) Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J. Nutr. Biochem., 18, 113–119.
32. Lloyd-Evans, E., Morgan, A.J., He, X., Smith, D.A., Elliot-Smith, E., Sillence, D.J., Churchill, G.C., Schuchman, E.H., Galione, A. and Platt, F.M. (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med., 14, 1247–1255.
33. Canfran-Dunque, A., Pastor, O., Quintana-Portillo, R., Lerma, M., de la Pena, G., Martin-Hidalgo, A., Fernandez-Hernando, C., Lasuncion, M.A. and Busto, R. (2014) Curcumin promotes exosomes/microvesicles secretion that attenuates lysosomal cholesterol traffic impairment. Mol. Nutr. Food Res., 58, 687–697.
34. Sun, Y., Ran, H., Zamzow, M., Kitatani, K., Skelton, M.R., Williams, M.T., Vorhees, C.V., Witte, D.P., Hannun, Y.A. and Grabowski, G.A. (2010) Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum. Mol. Genet., 19, 634–647.
35. Yoneshige, A., Suzuki, K., Suzuki, K. and Matsuda, J. (2010) A mutation in the saposin C domain of the sphingolipid activator protein (Prosaposin) gene causes neurodegenerative disease in mice. J. Neurosci. Res., 88, 2118–2134.
36. Anand, P., Kunnumakkara, A.B., Newman, R.A. and Aggarwal, B.B. (2007) Bioavailability of curcumin: problems and promises. Mol. Pharm., 4, 807–818.
37. Shakibaei, M., Buhrmann, C., Kraehe, P., Shayan, P., Lueders, C. and Goel, A. (2014) Curcumin chemosensitizes 5-fluorour-acil resistant MMR-deficient human colon cancer cells in high density culture. PLOS ONE, 9, e85397. doi: 10.1371.
38. Sanmukhani, J., Satodia, V., Trivedi, J., Patel, T., Tiwari, D., Panchal, B., Goel, A. and Tripathi, C.B. (2014) Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother. Res., 28, 579–585.
39. Peake, K.B. and Vance, J.E. (2012) Normalization of cholesterol homeostasis by 2-hydroxypropyl-β-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice. J. Biol. Chem., 287, 9290–9298.
40. Sarkar, S., Carroll, B., Buganim, Y., Maetzel, D., Ng, A.H., Cassady, J.P., Cohen, M.A., Chakraborty, S., Wang, H., Spooner, E. et al. (2013) Impaired autophagy in the lipid storage disorder Niemann-Pick type C1 disease. Cell Rep., 5, 1302–1315.
41. Song, W., Wang, F., Lofti, P., Sardiello, M. and Segatori, L. (2014) 2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J. Biol. Chem., 289, 10211–10222.
42. Barrett, A.J. and Kirschke, H. (1981) Cathepsin B, Cathepsin H, and Cathepsin L. Methods Enzimol., 80, 535–561.
43. Yasuda, Y., Kageyama, T., Akamine, A., Shibata, M., Kominami, E., Uchiyama, Y. and Yamamoto, K. (1999) Characterization of new fluorogenic substrates for the rapid and sensitive assay of cathepsin E and cathepsin D. J. Biochem., 125, 1137–1143.